← Deal Flow

Neomorph

Deep
2Rounds
1Articles
General InformationNeomorph appears to be an early-stage deep-tech company, though specific details about its location, employee count, and founding date are not publicly confirmed in accessible sources.
Funding & FinancialsNo confirmed funding information is available for Neomorph from public sources, suggesting it may be in pre-seed or stealth stage.
Leadership & TeamLeadership and team composition for Neomorph could not be verified from available public information.
Recent ActivityRecent activity or product developments for Neomorph are not documented in accessible public sources, consistent with an early-stage or stealth-mode operation.

Highlights

Total Raised
—
2 rounds
Latest Round
$100
May 2, 2026
Stage
—
deep-tech
Employees
—
Headquarters
—
News Coverage
1 articles
Last: 6mo ago
Talent Signals
1 moves
SEC Filings
—

Backers

Alexandria Venture Investments
Binney Street Capital
Deerfield Management
Longwood Fund
Regeneron Ventures

Funding History

$100
2026
Series B
$100
2026
Series B
SEC Form D   Editorial
May 2, 2026
$100 millionSeries B · Editorial

Investors: Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital

Biotech company developing molecular glue degrader therapies raised $100 million Series B to advance its pipeline for cancer treatment.

Apr 14, 2026
$100 millionSeries B · Editorial

Investors: Deerfield Management, Regeneron Ventures, Longwood Fund, Alexandria Venture Investments, Binney Street Capital

Neomorph closed a $100M Series B led by Deerfield Management to advance NEO-811 molecular glue degrader in Phase 1/2 trials for renal cancer, with backing from Regeneron Ventures and Dana-Farber's Binney Street Capital.

View article →

News Coverage 1

Deep6mo ago

Neomorph Closes $100M Series B With First Patient Dosed

Neomorph raised $100M in Series B funding to advance NEO-811, a molecular glue degrader with a first-in-human patient already dosed in Phase 1/2 trials for renal cancer, backed by Deerfield Management and pharma giants Novo Nordisk, Biogen, and AbbVie.

Talent 1

Cam Wheeler
appointmentChair of Neomorph's boardApr 14, 2026
Source →

Similar Companies 6

RebellionsSeries BInfleqtionSeries BQuantinuum Ltd.Series CQuEra ComputingSeries BXanadu Quantum Technologies LimitedSeries CPsiQuantumSeries D+